https://www.insurerbrain.com/w/index.php?action=history&feed=atom&title=Definition%3AAntitrust_review 2026-04-30T08:51:34Z Revision history for this page on the wiki MediaWiki 1.43.8 https://www.insurerbrain.com/w/index.php?title=Definition:Antitrust_review&diff=10357&oldid=prev 2026-03-11T16:30:37Z

<p>Bot: Creating new article from JSON</p> <p><b>New page</b></p><div>🔍 &#039;&#039;&#039;Antitrust review&#039;&#039;&#039; is the regulatory and legal examination process that evaluates whether a proposed transaction or business practice in the insurance industry — most commonly a [[Definition:Merger and acquisition (M&amp;A) | merger, acquisition]], or significant consolidation — could substantially lessen competition or create a monopoly in a relevant market. In addition to the standard federal review conducted by the Department of Justice (DOJ) or the Federal Trade Commission (FTC), insurance transactions frequently face a parallel layer of scrutiny from [[Definition:Insurance department | state insurance departments]] under [[Definition:Change of control | change-of-control]] statutes, making the review process in this sector more complex than in most other industries.<br /> <br /> ⚙️ When a major deal is announced — say, one [[Definition:Insurance carrier | carrier]] acquiring another or a [[Definition:Private equity | private equity]] firm purchasing an [[Definition:Insurance holding company | insurance holding company]] — the parties typically file a Hart-Scott-Rodino notification with federal authorities and simultaneously submit [[Definition:Form A | Form A]] filings (or equivalent) with each state where the target insurer is domiciled or licensed. Federal reviewers assess market concentration, pricing power, and competitive effects using standard antitrust frameworks. State [[Definition:Insurance commissioner | insurance commissioners]], meanwhile, evaluate the transaction&#039;s impact on [[Definition:Policyholder | policyholders]], [[Definition:Solvency | solvency]], and the broader public interest. If concerns arise at either level, the reviewing body may demand divestitures, impose conditions, or block the deal outright. The dual-track nature of this process can extend timelines significantly and requires careful coordination by legal and regulatory affairs teams.<br /> <br /> 📈 With consolidation accelerating across the insurance value chain — from [[Definition:Insurance broker | brokerages]] and [[Definition:Managing general agent (MGA) | MGAs]] to [[Definition:Reinsurance | reinsurers]] and [[Definition:Insurtech | insurtech]] platforms — antitrust review has become a defining feature of deal-making strategy. Acquirers must model potential regulatory objections before signing, build remedy packages in advance, and factor extended review periods into transaction economics. Recent high-profile reviews in the brokerage and specialty markets have demonstrated that regulators are willing to scrutinize not just [[Definition:Premium | premium]] market share but also control over distribution, data assets, and [[Definition:Underwriting capacity | underwriting capacity]]. Ignoring the antitrust dimension of a deal is a recipe for costly delays or outright failure.<br /> <br /> &#039;&#039;&#039;Related concepts:&#039;&#039;&#039;<br /> {{Div col|colwidth=20em}}<br /> * [[Definition:Antitrust law]]<br /> * [[Definition:Merger and acquisition (M&amp;A)]]<br /> * [[Definition:Change of control]]<br /> * [[Definition:Form A]]<br /> * [[Definition:Insurance holding company]]<br /> * [[Definition:Insurance regulation]]<br /> {{Div col end}}</div>

PlumBot